Literature DB >> 2114470

A two-phase linear regression model for biologic half-life data.

M L Lee1, W Y Poon, H S Kingdon.   

Abstract

In estimating the biologic half-life of an infused drug or biologic agent, one very frequently used model is the biexponential, which reflects a two-compartment physiologic model. The difficulty in using this model is that it is nonlinear in the parameters and requires relatively sophisticated analysis. Furthermore, an interval estimate is not usually reported. We propose the use of a two-phase linear regression approach, which is tantamount to breaking down the model into two straight lines based on the selection of the logarithm of concentration as the ordinate and time as the abscissa. We show how to determine the joint or changeover point for the two lines using a simple iterative procedure, how to select between a one-phase and a two-phase model, and how to provide a simple confidence interval estimate for half-life when it exists. An example using data from a study of Factor VIII pharmacokinetics is given.

Mesh:

Substances:

Year:  1990        PMID: 2114470

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  13 in total

1.  Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism.

Authors:  H M Chapel; M Lee
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

2.  Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Saeid Taheri; N Jon Shah; Gary A Rosenberg
Journal:  Magn Reson Imaging       Date:  2016-04-22       Impact factor: 2.546

3.  Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency.

Authors:  Joseph A Church; Heinz Leibl; Mark R Stein; Isaac R Melamed; Arye Rubinstein; Lynda C Schneider; Richard L Wasserman; Borislava G Pavlova; Karl Birthistle; Marianne Mancini; Sandor Fritsch; Lisa Patrone; Kerry Moore-Perry; Hartmut J Ehrlich
Journal:  J Clin Immunol       Date:  2006-05-17       Impact factor: 8.317

4.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

5.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Authors:  S Björkman; V S Blanchette; K Fischer; M Oh; G Spotts; P Schroth; S Fritsch; L Patrone; B M Ewenstein; P W Collins
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824

6.  Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.

Authors:  Johnny Mahlangu; Howard Levy; Marina V Kosinova; Heghine Khachatryan; Bartosz Korczowski; Levani Makhaldiani; Genadi Iosava; Martin Lee; Frank Del Greco
Journal:  Res Pract Thromb Haemost       Date:  2021-08-17

7.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.

Authors:  L A Valentino; V Mamonov; A Hellmann; D V Quon; A Chybicka; P Schroth; L Patrone; W-Y Wong
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

8.  Novel liposomal formulation for targeted gene delivery.

Authors:  Véronique Rivest; Alix Phivilay; Carl Julien; Sandra Bélanger; Cyntia Tremblay; Vincent Emond; Frédéric Calon
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.580

9.  Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.

Authors:  Zhen-Ping Chen; Pei-Jing Li; Gang Li; Ling Tang; Ying-Zi Zhen; Xin-Yi Wu; Xiao-Ling Cheng; Koon Hung Luke; Victor S Blanchette; Man-Chiu Poon; Qiu-Lan Ding; Run-Hui Wu
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628

10.  Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.

Authors:  Timothy C Nichols; Howard Levy; Elizabeth P Merricks; Robin A Raymer; Martin L Lee
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.